Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities.
about
Association of TNF-alpha genetic polymorphism with HLA DPB1*0301Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivityDifferential cerebral cortex transcriptomes of baboon neonates consuming moderate and high docosahexaenoic acid formulas.Asthma-related comorbidities.Interleukin-1β mediates virus-induced m2 muscarinic receptor dysfunction and airway hyperreactivity.Mega-dose vitamin C attenuated lung inflammation in mouse asthma model.Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge.Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblastsCaveolin-1 in cytokine-induced enhancement of intracellular Ca(2+) in human airway smooth muscle.Drug development for severe asthma: what are the metrics?Overexpression of programmed cell death 5 in a mouse model of ovalbumin-induced allergic asthma.Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma.High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells.Sinomenine attenuates airway inflammation and remodeling in a mouse model of asthma.Novel medications for asthma: a look at the future.Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: possible implications of tumor necrosis factor-alpha and CXC chemokinesAirway remodeling and lack of bronchodilator response in steroid-resistant asthma.Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE.A novel function of IL-33: suppression of innate antiviral immunity.Genetics of asthma: a molecular biologist perspectiveThe Role of IL-17 in a Lipopolysaccharide-Induced Rhinitis Model.S100A8/A9: a mediator of severe asthma pathogenesis and morbidity?Increased Autophagy-Related 5 Gene Expression Is Associated with Collagen Expression in the Airways of Refractory Asthmatics.Growing old with asthma: what are the changes and challenges?Asthma in pediatric patients: unmet need and therapeutic options.What's new in asthma pathophysiology and immunopathology?Bronchial thermoplasty: a new treatment paradigm for severe persistent asthma.Anti-fibrotic actions of relaxin.Genetic factors in the treatment of bronchial asthma.The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1.Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.Airway epithelium stimulates smooth muscle proliferation.Clinical phenotypes of severe asthma.Inactivation of capsaicin-sensitive nerves reduces pulmonary remodeling in guinea pigs with chronic allergic pulmonary inflammation.Counter regulation of the high affinity IgE receptor, FcepsilonRI, on human airway dendritic cells by IL-4 and IL-10.The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.Lidocaine-derivative JMF2-1 prevents ovalbumin-induced airway inflammation by regulating the function and survival of T cells.The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2.Asthma and autoimmunity: a complex but intriguing relation.
P2860
Q28200594-C1F9C40F-E485-4F3A-A41D-09A833A9348EQ28221900-8CA1C1E2-8A7F-4A97-B738-FB1B276D6F70Q33281757-F526CEC9-C091-4D00-90CD-8FCD6D04CE39Q34195201-998C5894-AB1E-4AD3-85FF-31658067EB64Q34305545-3D17DE5D-8394-4796-BAD0-37A7F21025F6Q34517358-A295A761-BE38-43CA-AFBF-D1E3848A0B64Q34541136-9782D9FF-565E-4652-A0B7-88AF5134F293Q35213717-B320AB76-9D68-4D5A-8126-D96A34723F60Q35325103-A5D1B5CB-C7E4-4380-AC56-CDBBB2460074Q36058940-5A7D9FAF-333C-4FC3-BF55-C930F3F53971Q36193355-1FDCE32F-B4CE-4722-AB49-7E966E3B90F1Q36326895-F52497B5-8A0B-4A19-9B90-47DB7A5B9720Q36438398-960C396F-D7B3-4966-8103-62649D41CF1BQ36623919-E4A6AC4C-C6F3-427A-A871-7C2AC635F696Q36821380-595CA8F0-DB5D-4730-BEE1-4EC34EF2E1DFQ37115840-5244A80C-9477-4B40-AAFC-911562E01702Q37230591-18C89E6E-77B6-425A-BE5F-8D99B32E2314Q37337010-8A4219C9-4CD0-40D6-ACC8-1AF7E397CF36Q37411105-D32C5940-9A69-4F74-A13D-045E1F2F24F4Q37472230-D2072ACB-9C91-40DA-8EC1-ABE50C825890Q37606275-49C80648-57AC-45D9-8579-92A1E2C6E786Q37629632-9F0BC488-D15B-4B43-9FE0-B341801E00FBQ37729501-257AB1E5-531C-4293-981D-13D803BB5B8EQ37734453-0F37EA14-7B18-4F19-A3EF-8EB7AE609C9CQ37781216-5CC41A0D-8522-4C8C-BA23-CB43F28690A6Q37798030-FCD9FAB1-8CBF-42E1-A33D-793FDEDC0CC7Q37959341-653EDF05-A94D-4772-B525-17535D260525Q38850557-6FD00653-49B4-4782-B054-F53F04FBD916Q40292888-4CC67B2C-4FE2-40B0-8317-01409A3F28E1Q40384438-2ADFEEF2-31A5-4A83-84ED-FAEB1A53466AQ41832184-4E38C7F5-DEDB-477B-88A7-62E8501FD4B1Q42553520-DB4E23D6-73F0-4362-8424-211047E068DFQ46266124-69D4A622-B907-4CC0-8439-3BD14CA6113CQ46494053-B9605EED-C746-44A6-B092-26BC2C14FBE1Q47963657-0012240F-B4B2-476A-83B8-FFDDC018F0B8Q48165386-E780B86A-A1F0-4663-A3C5-5A26ECCBF030Q48324151-53A5E130-B65F-4340-9FC4-271F3D57EF65Q50723376-B051F34E-4167-446B-BE54-B66446E2DB80Q50950460-EFB82D28-A181-44C5-A16B-0F5E8F908739Q51676365-BB1F93EF-39A0-4DCD-9EDF-EB31792592F8
P2860
Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Understanding the pathophysiol ...... new therapeutic opportunities.
@ast
Understanding the pathophysiol ...... new therapeutic opportunities.
@en
type
label
Understanding the pathophysiol ...... new therapeutic opportunities.
@ast
Understanding the pathophysiol ...... new therapeutic opportunities.
@en
prefLabel
Understanding the pathophysiol ...... new therapeutic opportunities.
@ast
Understanding the pathophysiol ...... new therapeutic opportunities.
@en
P2093
P1476
Understanding the pathophysiol ...... new therapeutic opportunities.
@en
P2093
Donna E Davies
Hans Michael Haitchi
Peter H Howarth
Suresh Babu
Susan Wilson
P304
496-506; quiz 507
P356
10.1016/J.JACI.2006.01.039
P407
P577
2006-03-01T00:00:00Z